3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase NA
3
Phase 4
3
Phase 1
2
Phase 2/3
1
Phase 1/2
1
Status
Completed
2
Terminated
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Neoplasms
3
Nausea
3
Vomiting
2
Multiple Myeloma
2
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pain, Postoperative
1
Pain
1
Neuralgia
1
Lung Neoplasms
1
Leukemia, Biphenotypic, Acute
1
Intestinal Diseases
1
Inflammatory Bowel Diseases
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Diseases
1
Crohn Disease
1
Colorectal Neoplasms
1
Interventions
Dexamethasone
8
Oxycodone
6
Epoetin Alfa
5
Propofol
4
Palonosetron
4
Meropenem
4
Zoledronic Acid
3
Vancomycin
3
Sevoflurane
3
Ondansetron
3
Naloxone
3
Everolimus
3
Ciprofloxacin
3
Cholecalciferol
3
Ceftazidime
3
Cefepime
3
Calcium Dobesilate
3
Bevacizumab
3
Aspirin
3
Aprepitant
3
peginterferon alfa-2a
2
edoxaban
2
apixaban
2
apatinib
2
Vitamin B 12
2
Vincristine
2
Tobacco Use Cessation Devices
2
Teicoplanin
2
Tablets
2
Surgical Procedures, Operative
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 4
×
Neoplasms
×
Calcium Dobesilate
×
Clear all
NCT00588835
2020-11-30
ACE
Radboud University Medical Center
Phase 4
Terminated
20 enrolled
NCT02815319
2020-04-28
REaCT-dex
Ottawa Hospital Research Institute
Phase 4
Completed
60 enrolled
NCT01636947
2018-09-25
KMEC
Merck Sharp & Dohme LLC
Phase 4
Completed
494 enrolled
14 charts